Dr Grégoire Pavé is an analyst in the Life Sciences team at Hardman & Co, and has considerable experience in the field of drug discovery and development.
In 2003, he enrolled in a team-leader post-doctoral position at Imperial College London, working on natural product synthesis. In 2005, he joined Cancer Research Technology, the development and commercial arm of Cancer Research UK, where he was involved in multiple oncology projects. Greg has broad experience in drug discovery and development projects, from target identification and validation through to clinical trials. He has also gained valuable experience in evaluating life science projects and their commercial opportunities. In addition, he has played a role of reviewer in peer-review journals from the American Chemical Society. He is also an author of 14 scientific papers and owner of four patents.
Greg joined Hardman & Co in March 2016. He has a PhD in Medicinal Chemistry from the University of Orléans in France, and holds the IMC and PRINCE2 qualifications.